Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy Candidates
Programs receiving funding include those developing company’s proprietary cryopreserved NK and gamma delta T-cell candidatesSAN MATEO, Calif., March 16, 2021...